Biotech company Regeneron (NASDAQ: REGN) will be reporting earnings this Friday before market open. Here’s what investors should know.

Regeneron beat analysts’ revenue expectations by 5.1% last quarter, reporting revenues of $3.75 billion, flat year on year. It was an incredible quarter for the company, with an impressive beat of analysts’ revenue estimates and a beat of analysts’ EPS estimates.

Is Regeneron a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, analysts are expecting Regeneron’s revenue to be flat year on year at $3.78 billion, slowing from the 10.3% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $10.64 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Regeneron has missed Wall Street’s revenue estimates twice over the last two years.

With Regeneron being the first among its peers to report earnings this season, we don’t have anywhere else to look to get a hint at how this quarter will unravel for biotechnology stocks. However, investors in the segment have had steady hands going into earnings, with share prices flat over the last month. Regeneron is down 3.1% during the same time and is heading into earnings with an average analyst price target of $831.38 (compared to the current share price of $753.64).

Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.